Subgroup analysis revealed that roxadustat significantly increase of Hb level compared with placebo in the NDD-CKD patients (WMD: 1.47; 95% CI: 0.78–2.17; p < 0.0001; with heterogeneity [p < 0.00001]; Figure 5 and Table 3) but not for DD-CKD patients. The gene discussed is GSTM1; the disease is chronic kidney disease.